Source and scope
This summary is bounded to the recommendations, population and decisions covered by Focused allergic rhinitis practice parameter for Canada. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian rhinitis parameter
Source-attributed clinical priorities
- Confirm an allergic symptom pattern and relevant triggers while considering infection, medication, structural disease and asthma.
- Use allergen avoidance where feasible, intranasal corticosteroid or other therapy matched to severity and preference, with technique reviewed.
- Arrange allergy assessment when diagnosis is uncertain, symptoms remain uncontrolled or immunotherapy is being considered.
- Persistent nasal obstruction, recurrent unilateral bleeding or loss of smell warrants assessment beyond allergy treatment.
sources for this section:Canadian rhinitis parameter
Practical assessment and management workflow
1
Identify seasonal or perennial triggers, eye symptoms, asthma, sleep and occupational exposure.
2
Examine nasal mucosa and consider testing only when it will change avoidance or immunotherapy.
3
Teach correct intranasal corticosteroid technique and combine non-sedating treatment according to severity.
4
Review adherence and response and refer uncertain, refractory or immunotherapy-eligible disease.
sources for this section:Canadian rhinitis parameter
Safety, red flags and urgent escalation
- Escalate acute breathing compromise or systemic anaphylaxis rather than treating as rhinitis.
- Avoid chronic topical decongestants because rebound congestion can develop.
- Consider asthma control whenever allergic rhinitis and lower-airway symptoms coexist.
sources for this section:Canadian rhinitis parameter
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian rhinitis parameter
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian rhinitis parameter
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Allergy, Asthma & Clinical ImmunologyFocused allergic rhinitis practice parameter for Canadaaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.